Direct access to validated botanical preclinical screening, toxicological dossiers, chromatographic development, and multi-scale OEM production units.
De-risking drug discovery and commercialization through integrated phytochemical isolation, non-clinical pharmacological validation, and agile scale-up manufacturing.
Traditional OEM relationships historically centered on passive contract manufacturing based entirely on client-supplied blueprints. Today's high-barrier bio-pharmaceutical and specialized nutraceutical sectors require Contract Development and Manufacturing Organisations (CDMOs) that operate as strategic innovation engines. MedGence integrates deep CRO analytical rigor with commercial scale-up execution, resolving complex phytochemical stability and bioavailability bottlenecks before initial pilot runs begin.
Natural compounds feature structural complexities that often confound traditional small-molecule synthesis pipelines. Sourcing batch variations, labile polyphenol profiles, and isomeric active fractions present substantial operational risk. By integrating comprehensive in vitro screening, pharmacokinetics, and animal safety profiling within the development phase, our CDMO framework eliminates false leads early, reducing CMC development cycles by up to 40%.
A successful commercial launch is impossible without exhaustive Chemistry, Manufacturing, and Controls (CMC) documentation. As an authoritative CDMO partner, MedGence provides end-to-end analytical traceability, establishing validated chromatographic fingerprints, degradation kinetics, stress testing dossiers, and ICH Q2(R1) analytical validations necessary to withstand rigorous scrutiny by global regulatory authorities including FDA, EMA, and NMPA.
Capitalizing on domestic agricultural terroir, deep technical talent, and massive scale-up infrastructure to deliver cost-optimized, highly standardized natural medicines.
China hosts over 11,000 medicinal plant species across diverse climatic biomes. Our direct integration with GAP-certified cultivation bases across Yunnan, Sichuan, Hunan, and Changbai Mountain ensures year-round harvest consistency, trace origin authentication, and sustainable conservation of wild resources.
From 50-liter pilot vessels to 10-ton automated continuous countercurrent extraction lines, our facilities transition bench-top protocols to multi-metric-ton output in weeks rather than quarters. High thermal efficiency and closed-loop solvent regeneration slash environmental impact and processing overhead.
Vertical supply integration avoids secondary trading brokers. Sourcing directly from verified cooperative farm bases, combined with energy-efficient extraction utilities and solvent-recovery yields exceeding 95%, secures a 25% to 45% production cost advantage for international brand owners.
Operating near major international shipping clusters in central and coastal China ensures streamlined customs clearing, bonded temperature-controlled warehousing, and cold-chain air freight dispatch. Finished active ingredients arrive with pre-cleared phytosanitary and export permits.
Overcoming cross-border regulatory variance through meticulous compliance alignment across North America, Europe, Asia-Pacific, and emerging markets.
Our facilities operate strictly under dual pharmaceutical and dietary supplement cGMP guidelines, fulfilling US FDA 21 CFR Part 111 & Part 210/211, EU EMA Annex 7 (Herbal Medicinal Products), and ISO 17025 laboratory accreditation. Batch records are maintained in complete ALCOA+ data integrity compliance, facilitating on-site and remote unannounced regulatory audits.
Botanical products are susceptible to environmental accumulation. Every batch undergoes rigorous ICP-MS profiling for heavy metals (Pb, As, Cd, Hg conforming to USP <232>/<233>), multi-residue GC-MS/MS testing for over 500 pesticide entities, HPLC mycotoxin quantification (Aflatoxins B1, B2, G1, G2, Ochratoxin A), and pathogen screens (Salmonella, E. coli, Yeast/Mold).
We implement defense-grade intellectual property compartmentalization. Client proprietary formulations, molecular target designs, and trade secrets are segregated on physically isolated servers with air-gapped laboratory networks. Strict bi-lingual Non-Disclosure Agreements (NDAs) govern every engagement from preliminary feasibility consultations to post-market surveillance.
International pharmaceutical conglomerates and leading FMCG brand owners maintain stringent vetting criteria. Here is how MedGence systematically answers critical procurement demands.
| Enterprise Procurement Metric | Global Brand Challenge & Risk Vector | MedGence CDMO Solution & Engineering Response |
|---|---|---|
| Batch-to-Batch Active Consistency | Secondary botanical metabolites fluctuate up to 300% across harvest cycles, causing variable potency and formulation drift. | Implementation of chemometric HPLC/HPTLC fingerprint standardization with active potency relative standard deviation (RSD) locked below 2.0% across all lots. |
| Tech Transfer Speed & Integrity | Protocol handoff friction between discovery research and factory production causes extensive delays and solvent yield collapse. | Unified CRO-to-CDMO technical governance: research teams oversee pilot scale-up directly, minimizing knowledge loss and reducing timeline to validation batches. |
| Traceability & ESG Governance | Opaque raw material brokers increase corporate vulnerability to deforestation, non-sustainable harvesting, and forced labor compliance liabilities. | Digital blockchain-enabled origin tracking, documented soil and pesticide environmental monitoring, and full compliance with Sedex/SMETA ethical sourcing audits. |
| Analytical Method Validation | Incompatible in-house testing methods generate inter-laboratory testing discrepancies and product release rejection at overseas ports. | Complete method development and co-validation across third-party reference labs (Eurofins, SGS) adhering strictly to ICH Q2(R1) validation guidelines. |
| Capacity Scalability & Redundancy | Sudden retail demand spikes lead to commercial stock-outs when partner manufacturing lines are capped or run single-facility operations. | Multi-site manufacturing redundancy with dual extraction facilities and modern automated cleanrooms capable of 1,500+ metric tons annual botanical throughput. |
Pioneering advanced extraction thermodynamics, artificial intelligence molecular screening, and green bioprocess technologies in natural product manufacturing.
By leveraging machine-learning models trained on tens of thousands of natural active fractions, we simulate ligand-receptor affinities, predict cell-signaling pathways, and forecast ADMET attributes in silico. This approach reduces traditional empirical cell-assay screening timelines from months to days, identifying lead plant compounds with surgical accuracy.
Regulatory bodies increasingly penalize petrochemical solvent residues. MedGence has industrialized supercritical CO₂ extraction with co-solvent modifiers alongside dynamic subcritical water systems. These green methodologies yield pristine active extracts free of petroleum fractions, drastically preserving thermolabile terpenes and bioflavonoids.
Modern buyers demand concrete Mode-of-Action (MoA) validation rather than generalized wellness claims. Integrating transcriptomic and metabolomic biomarker assays into our in vitro and animal studies allows us to map precise genetic and metabolic cascades, providing ironclad intellectual property backing for client patent filings.
Tailored formulations engineered for strict market-entry standards across pharmaceuticals, nutraceuticals, clinical nutrition, and dermocosmetics.
Formulated to meet US FDA 21 CFR Part 312 and EMA herbal medicinal product standards. We deliver Phase 1-to-4 clinical trial batches, stability studies (ICH Q1A), and comprehensive impurity profiling for registration trials.
Custom solid dosage (tablets, two-piece hard capsules, enteric-coated softgels) and micro-encapsulated water-dispersible powders. Optimized for high active loading, clean label excipient systems, and enhanced shelf stability.
Purified phyto-active fractions for dermatological topical use. Supported by in vitro human keratinocyte (HaCaT) anti-inflammatory testing, tyrosinase inhibition assays, trans-epidermal Franz cell diffusion, and cellular anti-aging studies.
Foods for Special Medical Purposes (FSMP) and therapeutic clinical drinks. Taste-masked, micro-emulsified botanical active complexes designed for metabolic, gastrointestinal, and oncological adjuvant dietary therapy.
Years of Natural Medicine CRO & CDMO Excellence
Phytochemical Researchers, Pharmacologists & Engineers
Leading Pharma Manufacturers & Tertiary Hospitals Served
Single-Herb Quality Standards & Process Monographs Formulated
Direct order pathways for contract testing, clinical trial protocols, active plant ingredient batches, and turnkey finished formulations.
In-depth answers addressing compliance validation, technology transfer timelines, analytical methodologies, and intellectual property containment.
Unlike traditional toll manufacturers who simply execute fixed client recipes, MedGence unites preclinical research (active ingredient screening, in vitro cell assays, toxicity, animal efficacy studies, HPLC/HPTLC method development) with commercial-scale extraction and dosage manufacturing. This closed loop ensures that formulations are optimized for stability, yield, and regulatory approval before industrial batch runs begin.
Botanical raw material variance is controlled through a three-tier standardization matrix: 1) Strict geographical and seasonal harvest origin locking; 2) Multi-wavelength HPLC and GC chromatographic fingerprinting to verify characteristic peak profiles; and 3) Quantitative assay standardization ensuring the target active markers fall within strict RSD thresholds (<2.0%) across metric-ton production lots.
Every delivery is supported by a comprehensive Certificate of Analysis (CoA) containing heavy metal testing (USP <232>/<233>), pesticide residue screening (500+ compounds), residual solvent clearance (USP <467>), microbiological plate counts, and HPTLC identity chromatograms. For pharmaceutical clients, complete CMC dossiers and Drug Master File (DMF) technical packages are supplied for FDA, EMA, or NMPA registration.
We execute enforceable non-disclosure and intellectual property assignment agreements governed by international arbitration standards. Internally, formula recipes and active molecule structures are segmented using code identifiers; only designated project lead scientists hold access privileges. No client formula is ever repurposed, shared, or commercialized without explicit authorization.
Standard analytical method validation and benchtop extraction feasibility typically require 3 to 5 weeks. Pilot scale-up validation (100kg to 500kg) spans approximately 4 to 6 weeks. Commercial-scale production runs for powders, liquids, or finished dosage forms require 6 to 8 weeks depending on raw material harvest schedules and customized packaging configurations.
Yes. In addition to GLP-compliant acute (LD50), sub-chronic, and Ames genotoxicity testing in animal models, we partner with premier clinical research centers and university teaching hospitals to execute Phase 1 pharmacokinetics, Phase 2 dose-ranging, Phase 3 multi-center efficacy trials, and Phase 4 post-market studies conforming to ICH-GCP guidelines.
Our finished dose manufacturing capacity includes solid oral forms (tablets, film-coated tablets, effervescent tablets, hard gelatin capsules, plant-based HPMC capsules), softgels (including specialized enteric formulations), oral liquids and functional shots (10ml to 50ml glass and PET ampoules), as well as multi-ingredient soluble granules packaged in stick packs or bulk foil bags.
